THOR-707, A Novel Not-alpha IL-2, Elicits Durable Pharmacodynamic Responses in Non-human Primates and, Efficacy as Single Agent and in Combination with Anti PD-1 in Multiple Syngeneic Mouse Models

Ingrid B. Joseph; Lina Ma; Jerod L. Ptacin; Carolina E. Caffaro; Hans R. Aerni; Kristine M. San Jose; Michael J. Pena; Robert W. Herman; Yelena Pavlova; David B. Chen; Ken Bragstad; Shukuan Li; Jasmine Nguyen; Laura K. Shawver; Lilia K. Koriazova; Marcos E. Milla

**RESULTS**

- A Single 3 mg/kg IV Dose of THOR-707 Expands Peripheral CD8+ T and NK Cells, Increasing Ki67 Expression in CT-26 Tumor-bearing Mice

**BACKGROUND**

**RESULTS**

- E-2 Has a Low Therapeutic Index Due to Its Dual Pharmacology at the High Affinity

**RESULTS**

- IL-2 Has A Low Therapeutic Index Due to Its Dual Pharmacology at the High Affinity

- THOR-707, A Novel Not-alpha IL-2, Elicits Durable Pharmacodynamic Responses in Non-human Primates and, Efficacy as Single Agent and in Combination with Anti PD-1 in Multiple Syngeneic Mouse Models

- THOR-707 Dosed Q2, 3 and 4W Elicited Similar Expansion of Peripheral CD8+ T Cells in NHP After Each Dose. With No Expansion of Eosinophils, THOR-707 Induced Monophasic Expansion in Day 7. Following Each Dose, Similar Expansion of Peripheral CD8+ T Cells was Observed in Day 7.

- THOR-707 Treated CT26 Tumor-bearing Mice

- Following each dose, Ki67 expression reached 60% and correlated with expansion of peripheral CD8+ T cells at sites of tumor and areas of necrosis.

- Downsampled Diversity – In both CT-26 and B16F-10 tumor-bearing mice, THOR-707 induced Ki67 in peripheral CD8+ T and NK cells ≥60%, resulting in the expansion of those populations in peripheral blood.

- Consistent with clonality data, repertoire diversity at all time points. Wilcox rank sum test used for 2-sample comparisons.

**CONCLUSIONS**

- THOR-707 does not skew signatures of induced T-cell exhaustion

- THOR-707 induced a 600% increase in tumor immune response across tissue and combined with CD-1 T-cell expansion of ≥100%.

- THOR-707 showed dose-dependent single agent antitumor activity. In combination with anti-PD1, THOR-707 showed single agent antitumor efficacy and increased tumor immune response in CT-26 tumor-bearing mice.

- THOR-707’s key characteristics

- THOR-707 does not skew signatures of induced T-cell exhaustion

- THOR-707 induces a 600% increase in tumor immune response across tissue and combined with CD-1 T-cell expansion of ≥100%.

- THOR-707 showed dose-dependent single agent antitumor activity. In combination with anti-PD1, THOR-707 showed single agent antitumor efficacy and increased tumor immune response in CT-26 tumor-bearing mice.